Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Blood Adv ; 8(1): 56-69, 2024 01 09.
Artículo en Inglés | MEDLINE | ID: mdl-37906522

RESUMEN

ABSTRACT: Cysteine is a nonessential amino acid required for protein synthesis, the generation of the antioxidant glutathione, and for synthesizing the nonproteinogenic amino acid taurine. Here, we highlight the broad sensitivity of leukemic stem and progenitor cells to cysteine depletion. By CRISPR/CRISPR-associated protein 9-mediated knockout of cystathionine-γ-lyase, the cystathionine-to-cysteine converting enzyme, and by metabolite supplementation studies upstream of cysteine, we functionally prove that cysteine is not synthesized from methionine in acute myeloid leukemia (AML) cells. Therefore, although perhaps nutritionally nonessential, cysteine must be imported for survival of these specific cell types. Depletion of cyst(e)ine increased reactive oxygen species (ROS) levels, and cell death was induced predominantly as a consequence of glutathione deprivation. nicotinamide adenine dinucleotide phosphate hydrogen oxidase inhibition strongly rescued viability after cysteine depletion, highlighting this as an important source of ROS in AML. ROS-induced cell death was mediated via ferroptosis, and inhibition of glutathione peroxidase 4 (GPX4), which functions in reducing lipid peroxides, was also highly toxic. We therefore propose that GPX4 is likely key in mediating the antioxidant activity of glutathione. In line, inhibition of the ROS scavenger thioredoxin reductase with auranofin also impaired cell viability, whereby we find that oxidative phosphorylation-driven AML subtypes, in particular, are highly dependent on thioredoxin-mediated protection against ferroptosis. Although inhibition of the cystine-glutamine antiporter by sulfasalazine was ineffective as a monotherapy, its combination with L-buthionine-sulfoximine (BSO) further improved AML ferroptosis induction. We propose the combination of either sulfasalazine or antioxidant machinery inhibitors along with ROS inducers such as BSO or chemotherapy for further preclinical testing.


Asunto(s)
Ferroptosis , Leucemia Mieloide Aguda , Humanos , Cisteína/metabolismo , Cisteína/farmacología , Especies Reactivas de Oxígeno/metabolismo , Antioxidantes , Cistationina/farmacología , Sulfasalazina/farmacología , Aminoácidos/farmacología , Glutatión/metabolismo , Glutatión/farmacología , Butionina Sulfoximina/farmacología , Leucemia Mieloide Aguda/tratamiento farmacológico
2.
Ned Tijdschr Geneeskd ; 156(34): A4343, 2012.
Artículo en Holandés | MEDLINE | ID: mdl-22914054

RESUMEN

Various calcium supplements are available for patients who have an indication for calcium suppletion. American guidelines and UpToDate recommend prescribing calcium citrate to patients who use antacids The rationale for this advice is that water-insoluble calcium carbonate needs acid for adequate absorption. No convincing scientific evidence supporting the advice to prescribe calcium citrate instead of calcium carbonate to patients who also take antacids is available, and therefore deserves further investigation. On the contrary, the fact that calcium carbonate does not need acid in order to be absorbed, has also not been proven. In clinical practise, it appears important that calcium is taken with meals in order to improve its absorption.


Asunto(s)
Antiácidos/efectos adversos , Carbonato de Calcio/farmacocinética , Citrato de Calcio/farmacocinética , Calcio de la Dieta/farmacocinética , Disponibilidad Biológica , Carbonato de Calcio/administración & dosificación , Citrato de Calcio/administración & dosificación , Calcio de la Dieta/administración & dosificación , Suplementos Dietéticos , Humanos , Absorción Intestinal
3.
Blood ; 119(13): 3050-9, 2012 Mar 29.
Artículo en Inglés | MEDLINE | ID: mdl-22327222

RESUMEN

Despite increasing knowledge on the regulation of hematopoietic stem/progenitor cell (HSPC) self-renewal and differentiation, in vitro control of stem cell fate decisions has been difficult. The ability to inhibit HSPC commitment in culture may be of benefit to cell therapy protocols. Small molecules can serve as tools to manipulate cell fate decisions. Here, we tested 2 small molecules, valproic acid (VPA) and lithium (Li), to inhibit differentiation. HSPCs exposed to VPA and Li during differentiation-inducing culture preserved an immature cell phenotype, provided radioprotection to lethally irradiated recipients, and enhanced in vivo repopulating potential. Anti-differentiation effects of VPA and Li were observed also at the level of committed progenitors, where VPA re-activated replating activity of common myeloid progenitor and granulocyte macrophage progenitor cells. Furthermore, VPA and Li synergistically preserved expression of stem cell-related genes and repressed genes involved in differentiation. Target genes were collectively co-regulated during normal hematopoietic differentiation. In addition, transcription factor networks were identified as possible primary regulators. Our results show that the combination of VPA and Li potently delays differentiation at the biologic and molecular levels and provide evidence to suggest that combinatorial screening of chemical compounds may uncover possible additive/synergistic effects to modulate stem cell fate decisions.


Asunto(s)
Diferenciación Celular/efectos de los fármacos , Hematopoyesis/efectos de los fármacos , Células Madre Hematopoyéticas/efectos de los fármacos , Litio/farmacología , Ácido Valproico/farmacología , Animales , Diferenciación Celular/fisiología , Células Cultivadas , Combinación de Medicamentos , Evaluación Preclínica de Medicamentos , Interacciones Farmacológicas , Femenino , Hematopoyesis/fisiología , Células Madre Hematopoyéticas/fisiología , Litio/administración & dosificación , Ratones , Ratones Endogámicos C57BL , Células Mieloides/efectos de los fármacos , Células Mieloides/fisiología , Fenotipo , Factores de Tiempo , Ácido Valproico/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA